1. Galunisertib combined with sorafenib affects in vivo tumor growth and immune landscape in hepatocellular carcinoma (HCC). (December 2016) Authors: Tijeras-Raballand, A.; Le Bitoux, M.A.; Maillard, A.; Albuquerque, M.; Colnot, N.; Barral, M.; Dohan, A.; Bonnin, P.; Pocard, M.; Benhadji, K.; Paradis, V.; Raymond, E.; Harari, A.; Faivre, S.; De Gramont, A. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S133 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Sequential transarterial chemoembolization and portal vein embolization before resection is a valid oncologic strategy for large unilobar hepatocellular carcinoma regardless of the tumor burden. (April 2016) Authors: Ronot, M.; Cauchy, F.; Breguet, R.; Allaham, W.; Sibert, A.; Paradis, V.; Soubrane, O.; Vilgrain, V. Journal: HPB Issue: Volume 18(2016)Supplement 1 Page Start: e199 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. When should we propose liver transplantation after liver resection for hepatocellular carcinoma?. (April 2016) Authors: Tribillon, E.; Barbier, L.; Scatton, O.; Goumard, C.; Irtan, S.; Perdigao-Cotta, F.; Paradis, V.; Belghiti, J.; Soubrane, O. Journal: HPB Issue: Volume 18(2016)Supplement 2 Page Start: e790 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗